Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03254784 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation
A Phase 1 study of Psoriasis and Systemic Lupus Erythematosus, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 49
- Enrollment target
- 1
- Study location
NCT03254784: Completed Phase 1 study of Psoriasis and Systemic Lupus Erythematosus, sponsored by Bristol-Myers Squibb.
NCT03254784 is a Phase 1 study of Psoriasis and Systemic Lupus Erythematosus that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 49 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03254784, a Phase 1 study of Psoriasis and Systemic Lupus Erythematosus, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 49 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate BMS-986165 tablet formulation versus BMS-986165 capsule formulation. This study will also evaluate the effect of a high-fat/ high-calorie meal and increased gastric pH on the BMS-986165 tablet formulation.
Conditions Studied
Interventions
- DRUG BMS-986165 Capsule
- DRUG BMS-986165 Tablet
Study Locations (1)
Kansas
- PRA Health Sciences - Lenexa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2017-09-13 |
| Est. Completion | 2017-11-15 |
| Phase | Phase 1 |
What the finished NCT03254784 record still lists
NCT03254784 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (90% lower).
The record links to 4 conditions, with Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which BMS-986165 Capsule is the first listed.
NCT03254784 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT03254784 about?
NCT03254784 is a clinical study titled "A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation". The purpose of this study is to evaluate BMS-986165 tablet formulation versus BMS-986165 capsule formulation. This study will also evaluate the effect of a high-fat/ high-calorie meal and increased gastric pH on the BMS-986165 tablet formulation.
What is the current status of trial NCT03254784?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2017-09-13. Estimated completion is 2017-11-15.
What conditions does trial NCT03254784 study?
This clinical trial studies the following conditions: Psoriasis, Systemic Lupus Erythematosus, Inflammatory Bowel Diseases, Arthritic Psoriasis.
What interventions are being tested in trial NCT03254784?
The interventions under investigation include: BMS-986165 Capsule (DRUG), BMS-986165 Tablet (DRUG).
Who is sponsoring clinical trial NCT03254784?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03254784 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03254784's enrollment target sits among peer trials
49 78th of 125 higher than 48 of 125 other Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Evaluate the Safety and Pharmacokinetics/Pharmacodynamics of HS-20118
RECRUITING · Phase 1
-
Study of SFA002 in Patients with Mild to Moderate Psoriasis Plaques
RECRUITING · Phase 1
-
Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis
RECRUITING · Phase 1
-
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
COMPLETED · Phase 1
-
Study Evaluating The Safety And Tolerability Of ILV-094 In Subjects With Psoriasis
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI